Search

Your search keyword '"Topaloglu, Rezan"' showing total 18 results
Start Over Author "Topaloglu, Rezan" Publisher wiley
18 results on '"Topaloglu, Rezan"'

1. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study

Author

Veys, Koenraad, primary, Zadora, Ward, additional, Hohenfellner, Katharina, additional, Bockenhauer, Detlef, additional, Janssen, Mirian C. H., additional, Niaudet, Patrick, additional, Servais, Aude, additional, Topaloglu, Rezan, additional, Besouw, Martine, additional, Novo, Robert, additional, Haffner, Dieter, additional, Kanzelmeyer, Nele, additional, Pape, Lars, additional, Wühl, Elke, additional, Harms, Erik, additional, Awan, Atif, additional, Sikora, Przemyslaw, additional, Ariceta, Gema, additional, van den Heuvel, Bert, additional, and Levtchenko, Elena, additional

Published
2022
Full Text
View/download PDF

2. Hospitalization following pediatric kidney transplantation: An international comparison among a Canadian pediatric transplant center, North American Pediatric Renal Trials and Collaborative Studies, and Cooperative European Pediatric Renal Transplant Initiative registry data

Author

Kim, Jin K., primary, Lorenzo, Armando J., additional, Tönshoff, Burkhard, additional, Chua, Michael E., additional, Raveendran, Lucshman, additional, Krupka, Kai, additional, Teoh, Chia Wei, additional, Ming, Jessica M., additional, Topaloglu, Rezan, additional, Dello Strologo, Luca, additional, Farhat, Walid A., additional, and Koyle, Martin A., additional

Published
2022
Full Text
View/download PDF

4. Mitigation of portal fibrosis and cholestatic liver disease in ANKS6 ‐deficient livers by macrophage depletion

Author

Airik, Merlin, primary, McCourt, Blake, additional, Ozturk, Tugba Tastemel, additional, Huynh, Amy B., additional, Zhang, Xiaoyi, additional, Tometich, Justin T., additional, Topaloglu, Rezan, additional, Ozen, Hasan, additional, Orhan, Diclehan, additional, Nejak‐Bowen, Kari, additional, Monga, Satdarshan P., additional, Hand, Timothy W., additional, Ozaltin, Fatih, additional, and Airik, Rannar, additional

Published
2022
Full Text
View/download PDF

5. A splice site mutation in theTSEN2causes a new syndrome with craniofacial and central nervous system malformations, and atypical hemolytic uremic syndrome

Author

Canpolat, Nur, primary, Liu, Dingxiao, additional, Atayar, Emine, additional, Saygili, Seha, additional, Kara, Nazli Sila, additional, Westfall, Trudi A., additional, Ding, Qiong, additional, Brown, Bartley J., additional, Braun, Terry A., additional, Slusarski, Diane, additional, Karli Oguz, Kader, additional, Ozluk, Yasemin, additional, Tuysuz, Beyhan, additional, Tastemel Ozturk, Tugba, additional, Sever, Lale, additional, Sezerman, Osman Ugur, additional, Topaloglu, Rezan, additional, Caliskan, Salim, additional, Attanasio, Massimo, additional, and Ozaltin, Fatih, additional

Published
2022
Full Text
View/download PDF

6. Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis/steroid‐resistant nephrotic syndrome

Author

Weber, Lutz T., primary, Tönshoff, Burkhard, additional, Grenda, Ryszard, additional, Bouts, Antonia, additional, Topaloglu, Rezan, additional, Gülhan, Bora, additional, Printza, Nikoleta, additional, Awan, Atif, additional, Battelino, Nina, additional, Ehren, Rasmus, additional, Hoyer, Peter F., additional, Novljan, Gregor, additional, Marks, Stephen D., additional, Oh, Jun, additional, Prytula, Agnieszka, additional, Seeman, Tomas, additional, Sweeney, Clodagh, additional, Dello Strologo, Luca, additional, and Pape, Lars, additional

Published
2020
Full Text
View/download PDF

8. Management of bone disease in cystinosis: Statement from an international conference

Author

Hohenfellner, Katharina, primary, Rauch, Frank, additional, Ariceta, Gema, additional, Awan, Atif, additional, Bacchetta, Justine, additional, Bergmann, Carsten, additional, Bechtold, Susanne, additional, Cassidy, Noelle, additional, Deschenes, Geroges, additional, Elenberg, Ewa, additional, Gahl, William A., additional, Greil, Oliver, additional, Harms, Erik, additional, Herzig, Nadine, additional, Hoppe, Bernd, additional, Koeppl, Christian, additional, Lewis, Malcolm A., additional, Levtchenko, Elena, additional, Nesterova, Galina, additional, Santos, Fernando, additional, Schlingmann, Karl P., additional, Servais, Aude, additional, Soliman, Neveen A., additional, Steidle, Guenther, additional, Sweeney, Clodagh, additional, Treikauskas, Ulrike, additional, Topaloglu, Rezan, additional, Tsygin, Alexey, additional, Veys, Koenraad, additional, Vigier, Rodo, additional, Zustin, Jozef, additional, and Haffner, Dieter, additional

Published
2019
Full Text
View/download PDF

9. Dyslipidemia after pediatric renal transplantation-The impact of immunosuppressive regimens

Author

Habbig, Sandra, Volland, Ruth, Krupka, Kai, Querfeld, Uwe, Dello Strologo, Luca, Noyan, Aytul, Yalcinkaya, Fatos, Topaloglu, Rezan, Webb, Nicholas J. A., Kemper, Markus J., Pape, Lars, Bald, Martin, Kranz, Birgitta, Taylan, Christina, Hoecker, Britta, Toenshoff, Burkhard, Weber, Lutz T., Habbig, Sandra, Volland, Ruth, Krupka, Kai, Querfeld, Uwe, Dello Strologo, Luca, Noyan, Aytul, Yalcinkaya, Fatos, Topaloglu, Rezan, Webb, Nicholas J. A., Kemper, Markus J., Pape, Lars, Bald, Martin, Kranz, Birgitta, Taylan, Christina, Hoecker, Britta, Toenshoff, Burkhard, and Weber, Lutz T.

Abstract

Dyslipidemia contributes to cardiovascular morbidity and mortality in pediatric transplant recipients. Data on prevalence and risk factors in pediatric cohorts are, however, scarce. We therefore determined the prevalence of dyslipidemia in 386 pediatric renal transplant recipients enrolled in the CERTAIN registry. Data were obtained before and during the first year after RTx to analyze possible non-modifiable and modifiable risk factors. The prevalence of dyslipidemia was 95% before engraftment and 88% at 1year post-transplant. Low estimated glomerular filtration rate at 1year post-transplant was associated with elevated serum triglyceride levels. The use of TAC and of MPA was associated with significantly lower concentrations of all lipid parameters compared to regimens containing CsA and mTORi. Immunosuppressive regimens consisting of CsA, MPA, and steroids as well as of CsA, mTORi, and steroids were associated with a three- and 25-fold (P<.001) increased risk of having more than one pathologic lipid parameter as compared to the use of TAC, MPA, and steroids. Thus, amelioration of the cardiovascular risk profile after pediatric RTx may be attained by adaption of the immunosuppressive regimen according to the individual risk profile.

Published
2017

10. Dyslipidemia after pediatric renal transplantation-The impact of immunosuppressive regimens

Author

Habbig, Sandra, primary, Volland, Ruth, additional, Krupka, Kai, additional, Querfeld, Uwe, additional, Dello Strologo, Luca, additional, Noyan, Aytül, additional, Yalcinkaya, Fatos, additional, Topaloglu, Rezan, additional, Webb, Nicholas J. A., additional, Kemper, Markus J., additional, Pape, Lars, additional, Bald, Martin, additional, Kranz, Birgitta, additional, Taylan, Christina, additional, Höcker, Britta, additional, Tönshoff, Burkhard, additional, and Weber, Lutz T., additional

Published
2017
Full Text
View/download PDF

14. Carotid intima–media thickness in children and young adults with renal transplant: Internal carotid artery vs. common carotid artery

Author

Bilginer, Yelda, primary, Ozaltin, Fatih, additional, Basaran, Ceyla, additional, Aki, Tuncay Fazil, additional, Karabulut, Erdem, additional, Duzova, Ali, additional, Besbas, Nesrin, additional, Topaloglu, Rezan, additional, Ozen, Seza, additional, Bakkaloglu, Mehmet, additional, and Bakkaloglu, Aysin, additional

Published
2007
Full Text
View/download PDF

16. Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis/steroid-resistant nephrotic syndrome

Author

Weber, Lutz T., Toenshoff, Burkhard, Grenda, Ryszard, Bouts, Antonia, Topaloglu, Rezan, Guelhan, Bora, Printza, Nikoleta, Awan, Atif, Battelino, Nina, Ehren, Rasmus, Hoyer, Peter F., Novljan, Gregor, Marks, Stephen D., Oh, Jun, Prytula, Agnieszka, Seeman, Tomas, Sweeney, Clodagh, Dello Strologo, Luca, Pape, Lars, Weber, Lutz T., Toenshoff, Burkhard, Grenda, Ryszard, Bouts, Antonia, Topaloglu, Rezan, Guelhan, Bora, Printza, Nikoleta, Awan, Atif, Battelino, Nina, Ehren, Rasmus, Hoyer, Peter F., Novljan, Gregor, Marks, Stephen D., Oh, Jun, Prytula, Agnieszka, Seeman, Tomas, Sweeney, Clodagh, Dello Strologo, Luca, and Pape, Lars

Abstract

Recurrence of primary disease is one of the major risks for allograft loss after pediatric RTx. The risk of recurrence of FSGS/SRNS after pediatric RTx in particular can be up to 86% in idiopathic cases. There is a need for consensus recommendations on its prevention and treatment. The CERTAIN study group has therefore performed a thorough literature search based on the PICO model of clinical questions to formulate educated statements to guide the clinician in the process of decision-making. A set of educated statements on prevention and treatment of FSGS/SRNS after pediatric RTx has been generated after careful evaluation of available evidence and thorough panel discussion. We do not recommend routine nephrectomy prior to transplantation; neither do we recommend abstaining from living donation. Special attendance needs to be given to those patients who had already experienced graft loss due to FSGS/SRNS recurrence. Early PE or IA with or without high-dose CsA and/or rituximab seems to be most promising to induce remission. The educated statements presented here acknowledge that FSGS/SRNS recurrence after pediatric RTx remains a major concern and is associated with shorter graft survival or even graft loss. The value of any recommendation needs to take into account that evidence is based on cohorts that differ in ethnicity, pre-transplant history, immunosuppressive regimen, definition of recurrence (eg, clinical and/or histological diagnosis) and treatment modalities of recurrence.

17. Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis/steroid-resistant nephrotic syndrome

Author

Weber, Lutz T., Toenshoff, Burkhard, Grenda, Ryszard, Bouts, Antonia, Topaloglu, Rezan, Guelhan, Bora, Printza, Nikoleta, Awan, Atif, Battelino, Nina, Ehren, Rasmus, Hoyer, Peter F., Novljan, Gregor, Marks, Stephen D., Oh, Jun, Prytula, Agnieszka, Seeman, Tomas, Sweeney, Clodagh, Dello Strologo, Luca, Pape, Lars, Weber, Lutz T., Toenshoff, Burkhard, Grenda, Ryszard, Bouts, Antonia, Topaloglu, Rezan, Guelhan, Bora, Printza, Nikoleta, Awan, Atif, Battelino, Nina, Ehren, Rasmus, Hoyer, Peter F., Novljan, Gregor, Marks, Stephen D., Oh, Jun, Prytula, Agnieszka, Seeman, Tomas, Sweeney, Clodagh, Dello Strologo, Luca, and Pape, Lars

Abstract

Recurrence of primary disease is one of the major risks for allograft loss after pediatric RTx. The risk of recurrence of FSGS/SRNS after pediatric RTx in particular can be up to 86% in idiopathic cases. There is a need for consensus recommendations on its prevention and treatment. The CERTAIN study group has therefore performed a thorough literature search based on the PICO model of clinical questions to formulate educated statements to guide the clinician in the process of decision-making. A set of educated statements on prevention and treatment of FSGS/SRNS after pediatric RTx has been generated after careful evaluation of available evidence and thorough panel discussion. We do not recommend routine nephrectomy prior to transplantation; neither do we recommend abstaining from living donation. Special attendance needs to be given to those patients who had already experienced graft loss due to FSGS/SRNS recurrence. Early PE or IA with or without high-dose CsA and/or rituximab seems to be most promising to induce remission. The educated statements presented here acknowledge that FSGS/SRNS recurrence after pediatric RTx remains a major concern and is associated with shorter graft survival or even graft loss. The value of any recommendation needs to take into account that evidence is based on cohorts that differ in ethnicity, pre-transplant history, immunosuppressive regimen, definition of recurrence (eg, clinical and/or histological diagnosis) and treatment modalities of recurrence.

18. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.

Author

Veys K, Zadora W, Hohenfellner K, Bockenhauer D, Janssen MCH, Niaudet P, Servais A, Topaloglu R, Besouw M, Novo R, Haffner D, Kanzelmeyer N, Pape L, Wühl E, Harms E, Awan A, Sikora P, Ariceta G, van den Heuvel B, and Levtchenko E

Subjects
Infant, Newborn, Humans, Child, Preschool, Child, Adolescent, Young Adult, Adult, Cysteamine therapeutic use, Siblings, Cohort Studies, Retrospective Studies, Cystinosis drug therapy, Cystinosis genetics, Cystinosis complications, Fanconi Syndrome drug therapy, Fanconi Syndrome genetics, Kidney Failure, Chronic etiology
Abstract

Infantile nephropathic cystinosis (INC) is an inheritable lysosomal storage disorder characterized by lysosomal cystine accumulation, progressive kidney disease, and multiple extrarenal complications (ERCs). Cysteamine postpones the onset of end-stage kidney disease (ESKD) and reduces the incidence of ERCs; however, cysteamine is generally initiated upon establishment of the renal Fanconi syndrome (FS) and partial loss of kidney function, whereas data on long-term effects of cysteamine administered from neonatal age are lacking. An international multicenter retrospective cohort study of siblings with INC was set up to investigate the outcome in relation to age at initiation of cysteamine versus CTNS genotype, with attention to patients treated with cysteamine from neonatal age. None of the siblings treated from neonatal age (n = 9; age 10 ± 6 years) had reached ESKD, while 22% of their index counterparts (n = 9; age 14 ± 5 years) had commenced renal replacement therapy. Siblings treated with cysteamine from the onset of symptoms at a younger age compared with their index counterparts, reached ESKD at a significant older age (13 ± 3 vs. 10 ± 3 years, p = 0.002). In contrast, no significant difference in ERCs was observed between sibling and index patients, independently from the age at initiation of cysteamine. The CTNS genotype had no impact on the overall outcome in this cohort. In INC, presymptomatic treatment with cysteamine results in a better renal outcome in comparison to treatment initiated from the onset of symptoms. This justifies including cystinosis into newborn screening programs. SYNOPSIS: In infantile nephropathic cystinosis, presymptomatic treatment with cysteamine improves the renal outcome which justifies the inclusion of cystinosis into newborn screening programs., (© 2022 SSIEM.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results